Clinical Trial: QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Observational

Official Title: QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Brief Summary: This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.

Detailed Summary:
Sponsor: Bayer

Current Primary Outcome: Quality of life evaluated by several validated questionnaire [ Time Frame: Baseline, 3, 6, 9, 12 months (+/- 1 month) ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Information about safety of Betaferon in routine clinical use [ Time Frame: Baseline, 3, 6, 9, 12 months (+/- 1 month) ]

Original Secondary Outcome: Same as current

Information By: Bayer

Dates:
Date Received: February 18, 2010
Date Started: January 2011
Date Completion: December 2012
Last Updated: April 12, 2012
Last Verified: April 2012